Kala Pharmaceuticals (KALA) PT Raised to $22 at Oppenheimer, After Receiving FDA Approval
Tweet
Share
E-mailGet Alerts KALA Hot Sheet
Price: $0.92 --0%
Rating Summary:
5 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Rating Summary:
5 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 9
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois raised the price target on Kala Pharmaceuticals (NASDAQ: KALA) to $22.00 (from $21.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Volkswagen AG (VOW:GR) (VWAGY) PT Lowered to EUR120 at RBC Capital
- Mercedes-Benz Group (MBG:GR) (DDAIF) PT Raised to EUR54 at RBC Capital
- Palo Alto Networks (PANW) PT Raised to $434 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
